Palvella Therapeutics, Inc. PVLA 深 滬
已收盤 05-08 16:00:00 美东时间
121.29
+8.030
+7.09%
華盛通- 最 高121.72
- 今 開113.61
- 成交量 23.15万股
- 最 低 113.61
- 昨 收 113.26
- 總市值 17.37亿
- 52周最高 151.18
- 市盈率 靜 --
- 換手率 1.62%
- 52周最低 20.20
- 委 比 70.94%
- 總股本 1432.37万
- 歷史最高 151.18
- 量 比 0.85
- 振 幅 7.16%
- 歷史最低 11.17
- 每 手 1
- 風險率 36.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palvella Announces First Patients Dosed In LOTU, Multicenter Phase 2 Clinical Trial To Evaluate Safety And Efficacy Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Clinically Significant Angiokeratomas
Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.Phase 2 single-arm,
05-04 19:36
Palvella Therapeutics To Highlight Results From Phase 3 SELVA And Phase 2 TOIVA Studies Of QTORIN Rapamycin At ISSVA World Congress 2026
James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4:30 p.m. ETWAYNE, Pa., April 20, 2026 (GLOBE
04-20 19:32
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.
04-01 05:09
Palvella Therapeutics shares are trading higher. The company reported its Q4 financial results.
Palvella Therapeutics shares are trading higher. The company reported its Q4 fi...
04-01 00:35
Palvella Therapeutics Q4 EPS $(1.08) Misses $(0.91) Estimate
Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.91) by 18.29 percent. This is a 79.89 percent increase over losses of $(5.37) per
03-31 19:31
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Raises Price Target to $270
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $255 to $270.
03-24 23:22
Palvella Therapeutics Secures European Patent Covering Lead QTORIN Rapamycin Gel
Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular
03-16 19:37
